Pharsight

Biomarin Pharm patents expiration

1. Kuvan patents expiration

KUVAN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612073 BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
Nov, 2024

(5 months from now)

US7947681 BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
Nov, 2024

(5 months from now)

US8318745 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
Nov, 2024

(5 months from now)

US8067416 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(5 months from now)

US7566714 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(5 months from now)

USRE43797 BIOMARIN PHARM Methods of administering tetrahydrobiopterin
Nov, 2024

(5 months from now)

US9433624 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(5 months from now)

US7727987 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
Nov, 2024

(5 months from now)

US9433624

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
May, 2025

(11 months from now)

US7566714

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
May, 2025

(11 months from now)

US7612073

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
May, 2025

(11 months from now)

US7727987

(Pediatric)

BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
May, 2025

(11 months from now)

US8067416

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
May, 2025

(11 months from now)

US8318745

(Pediatric)

BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
May, 2025

(11 months from now)

USRE43797

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin
May, 2025

(11 months from now)

US7947681

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
May, 2025

(11 months from now)

US8003126 BIOMARIN PHARM Stable tablet formulation
Nov, 2025

(1 year, 5 months from now)

US7566462 BIOMARIN PHARM Stable tablet formulation
Nov, 2025

(1 year, 5 months from now)

US8003126

(Pediatric)

BIOMARIN PHARM Stable tablet formulation
May, 2026

(1 year, 11 months from now)

US7566462

(Pediatric)

BIOMARIN PHARM Stable tablet formulation
May, 2026

(1 year, 11 months from now)

US9216178 BIOMARIN PHARM Dry blend formulation of tetrahydrobiopterin
Nov, 2032

(8 years from now)

US9216178

(Pediatric)

BIOMARIN PHARM Dry blend formulation of tetrahydrobiopterin
May, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Apr 23, 2017
Pediatric Exclusivity(PED) Oct 23, 2017
Orphan Drug Exclusivity(ODE) Dec 13, 2014
New Chemical Entity Exclusivity(NCE) Dec 13, 2012

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

NCE-1 date: 23 October, 2016

Market Authorisation Date: 13 December, 2007

Treatment: To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption; To re...

Dosage: TABLET;ORAL; POWDER;ORAL

How can I launch a generic of KUVAN before it's drug patent expiration?
More Information on Dosage

KUVAN family patents

Family Patents

2. Voxzogo patents expiration

VOXZOGO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8198242 BIOMARIN PHARM Variants of C-type natriuretic peptide
Jun, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48267 BIOMARIN PHARM Variants of C-type natriuretic peptide
May, 2030

(5 years from now)

US9907834 BIOMARIN PHARM Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Aug, 2036

(12 years from now)

US10646550 BIOMARIN PHARM Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Aug, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 19, 2026
Orphan Drug Exclusivity(ODE-449) Oct 20, 2030
New Patient Population(NPP) Oct 20, 2026
Orphan Drug Exclusivity(ODE-387) Nov 19, 2028

Drugs and Companies using VOSORITIDE ingredient

NCE-1 date: 19 November, 2025

Market Authorisation Date: 19 November, 2021

Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

VOXZOGO family patents

Family Patents